July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Novel ex and in vivo methods for non-invasive longitudinal tracking of RPE dysmorphology following subretinal injections
Author Affiliations & Notes
  • Kevin Joseph Donaldson
    Ophthalmology, Emory University, Atlanta, Georgia, United States
  • Henry M Skelton
    Morehouse School of Medicine, Atlanta, Georgia, United States
  • Jana T Sellers
    Ophthalmology, Emory University, Atlanta, Georgia, United States
  • Hans Grossniklaus
    Ophthalmology, Emory University, Atlanta, Georgia, United States
  • J M Nickerson
    Ophthalmology, Emory University, Atlanta, Georgia, United States
  • Footnotes
    Commercial Relationships   Kevin Donaldson, None; Henry Skelton, None; Jana Sellers, None; Hans Grossniklaus, None; J Nickerson, None
  • Footnotes
    Support   NIH R01EY021592, R01EY016470, P30EY006360, and an unrestricted grant to the Department of Ophthalmology at Emory University from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4982. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kevin Joseph Donaldson, Henry M Skelton, Jana T Sellers, Hans Grossniklaus, J M Nickerson; Novel ex and in vivo methods for non-invasive longitudinal tracking of RPE dysmorphology following subretinal injections. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4982. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Retinal diseases and surgically-induced physical damage are associated with abnormal RPE morphology. Subretinal injections (SRIs) used in gene-delivery therapies are thought to be self-resolving and relatively innocuous. Recovery is assumed to occur shortly after reattachment of the retina. However, the time course and extent of RPE recovery have not been systematically described in the mouse with either histological or non-invasive techniques. We tested the hypothesis that the RPE remains in an abnormal state for much longer than previously expected.

Methods : Adult C57BL/6J mice received either SRI of Dulbecco’s PBS (n=12) or mock injection (n=10) in one eye, with the contralateral eye remaining naive. SD-OCT and fundoscopy was performed at multiple time points (0–60 days) post-procedure on all eyes. RPE flatmounts were prepared from each eye after the final imaging time-point. Confocal imaging of IHC labeling of alpha-catenin and ZO-1 enabled quantitative single-cell metrics to be obtained. We generated two distinct transgenic mouse lines with RPE-specific fluorescent protein expression (Best1-Confetti, Best1-ZsGREEN1) for in vivo longitudinal imaging. To verify morphology and condition of the RPE sheet at the level of individual cells, in vivo cSLO and fundoscopic images were then co-registered with post-mortem flatmounts.

Results : Retinal detachments resolved 8 days after SRI in DPBS and mock injection eyes, however abnormal RPE cell morphology (enlarged cell perimeter and area) persisted for up to 60 days post-procedure. Visible discoloration patterns in fundus images corresponded with regions of damage in flatmounts. It was possible to identify unique, individual, RPE cells in vivo with color fundoscopy and cSLO imaging for up to 4 weeks.

Conclusions : Here, we highlight the success of a novel, non-invasive technique that allows for simple, efficient, and repeated in vivo visualization of RPE over multiple weeks. Individual cells identified in live imaging can be subsequently co-registered in histological samples. Studies tracking in vivo RPE cell dynamics in disease models and after injury are now possible. Even after retinal detachments resolve, the underlying RPE remains abnormal for up to two months, much longer than previously thought. Therapeutic approaches employing SRIs may be negatively affected as evidenced by prolonged disruption of the RPE.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.